{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T13:48:36Z","timestamp":1764510516561},"reference-count":36,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1016\/j.critrevonc.2015.03.004","type":"journal-article","created":{"date-parts":[[2015,3,26]],"date-time":"2015-03-26T10:54:56Z","timestamp":1427367296000},"page":"243-250","source":"Crossref","is-referenced-by-count":6,"title":["Survey of expert opinions and related recommendations regarding bridging therapy using hypomethylating agents followed by allogeneic transplantation for high-risk MDS"],"prefix":"10.1016","volume":"95","author":[{"given":"Sang Kyun","family":"Sohn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joon Ho","family":"Moon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2015.03.004_bib0185","doi-asserted-by":"crossref","first-page":"30","DOI":"10.6004\/jnccn.2011.0005","article-title":"NCCN clinical practice guidelines in oncology: myelodysplastic syndromes","volume":"9","author":"Greenberg","year":"2011","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.critrevonc.2015.03.004_bib0190","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1182\/blood-2004-01-0338","article-title":"A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome","volume":"104","author":"Cutler","year":"2004","journal-title":"Blood"},{"issue":"Suppl. 2","key":"10.1016\/j.critrevonc.2015.03.004_bib0195","doi-asserted-by":"crossref","first-page":"S282","DOI":"10.1016\/j.clml.2013.07.012","article-title":"Allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes","volume":"13","author":"Oran","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.critrevonc.2015.03.004_bib0200","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.beha.2013.10.001","article-title":"The euphoria of hypomethylating agents in MDS and AML: is it justified","volume":"26","author":"Sekeres","year":"2013","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.critrevonc.2015.03.004_bib0205","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.beha.2012.10.007","article-title":"Can hypomethylating agents provide a platform for curative therapy in myelodysplastic syndromes","volume":"25","author":"Steensma","year":"2012","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.critrevonc.2015.03.004_bib0210","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s12185-014-1549-3","article-title":"Multicenter study evaluating the impact of hypomethylating agents as bridging therapy to hematopoietic stem cell transplantation in myelodysplastic syndromes","volume":"99","author":"Kim","year":"2014","journal-title":"Int J Hematol"},{"key":"10.1016\/j.critrevonc.2015.03.004_bib0215","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1200\/JCO.2012.48.0525","article-title":"Should cytoreductive treatment be performed before transplantation in patients with high-risk myelodysplastic syndrome?","volume":"31","author":"Alessandrino","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2015.03.004_bib0220","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/j.1600-0609.2011.01703.x","article-title":"Cytoreductive treatment with clofarabine\/ara-C combined with reduced-intensity conditioning and allogeneic stem cell transplantation in patients with high-risk, relapsed, or refractory acute myeloid leukemia and advanced myelodysplastic syndrome","volume":"88","author":"Buchholz","year":"2012","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.critrevonc.2015.03.004_bib0225","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/j.bbmt.2012.01.009","article-title":"Pretransplantation therapy with azacitidine vs induction chemotherapy and posttransplantation outcome in patients with MDS","volume":"18","author":"Gerds","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.critrevonc.2015.03.004_bib0230","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/MOH.0b013e32834ff562","article-title":"Transplantation for myelodysplastic syndrome in the era of hypomethylating agents","volume":"19","author":"Gerds","year":"2012","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.critrevonc.2015.03.004_bib0235","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1016\/j.bbmt.2014.06.023","article-title":"Are hypomethylating agents replacing induction-type chemotherapy before allogeneic stem cell transplantation in patients with myelodysplastic syndrome?","volume":"20","author":"Yakoub-Agha","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.critrevonc.2015.03.004_bib0240","first-page":"7","article-title":"Timing of allogeneic stem cell transplantation for myelodysplastic syndrome and aplastic anemia","volume":"7","author":"Cutler","year":"2014","journal-title":"Am Soc Hematol Educ Program"},{"key":"10.1016\/j.critrevonc.2015.03.004_bib0245","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1182\/blood-2013-08-496935","article-title":"How we treat higher-risk myelodysplastic syndromes","volume":"123","author":"Sekeres","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.03.004_bib0250","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1182\/blood-2013-12-542720","article-title":"Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R","volume":"123","author":"Della Porta","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.03.004_bib0255","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.bbmt.2008.10.012","article-title":"Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden","volume":"15","author":"Warlick","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.critrevonc.2015.03.004_bib0260","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1038\/sj.bmt.1704938","article-title":"Impact of disease burden at time of allogeneic stem cell transplantation in adults with acute myeloid leukemia and myelodysplastic syndromes","volume":"35","author":"Kebriaei","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.critrevonc.2015.03.004_bib0265","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1517\/13543784.2014.877887","article-title":"Clofarabine in the treatment of myelodysplastic syndromes","volume":"23","author":"Bryan","year":"2014","journal-title":"Expert Opin Invest Drugs"},{"key":"10.1016\/j.critrevonc.2015.03.004_bib0270","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1200\/JCO.2012.46.4222","article-title":"When azanucleoside treatment can be curative: nonintensive bridging strategy before allografting in older patients with myelodysplastic syndrome\/acute myeloid leukemia","volume":"31","author":"Lubbert","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2015.03.004_bib0275","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1182\/blood-2010-11-320093","article-title":"Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML","volume":"118","author":"Scandura","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.03.004_bib0280","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.bbmt.2014.02.008","article-title":"Pretransplantation 5-azacitidine in high-risk myelodysplastic syndrome","volume":"20","author":"Nishihori","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.critrevonc.2015.03.004_bib0285","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1182\/blood-2013-03-492884","article-title":"Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet","volume":"122","author":"Malcovati","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.03.004_bib0290","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1586\/17474086.2013.814849","article-title":"When is the optimal timing for allogeneic transplantation in the case of MDS patients treated with hypomethylating agents","volume":"6","author":"Sohn","year":"2013","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.critrevonc.2015.03.004_bib0295","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1016\/j.bbmt.2014.06.022","article-title":"Cytogenetics, donor type, and use of hypomethylating agents in myelodysplastic syndrome with allogeneic stem cell transplantation","volume":"20","author":"Oran","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.critrevonc.2015.03.004_bib0300","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/bmt.2009.134","article-title":"5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation","volume":"45","author":"Field","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.critrevonc.2015.03.004_bib0305","doi-asserted-by":"crossref","first-page":"4533","DOI":"10.1200\/JCO.2012.44.3499","article-title":"Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes: a study by the Societe Francaise de Greffe de Moelle et de Therapie-Cellulaire and the Groupe-Francophone des Myelodysplasies","volume":"30","author":"Damaj","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2015.03.004_bib0310","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1182\/blood-2009-12-257253","article-title":"In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia","volume":"116","author":"Choi","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.03.004_bib0315","doi-asserted-by":"crossref","first-page":"661","DOI":"10.2174\/15680096113139990005","article-title":"Optimizing outcomes following allogeneic hematopoietic progenitor cell transplantation in AML: the role of hypomethylating agents","volume":"13","author":"Martino","year":"2013","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.critrevonc.2015.03.004_bib0320","article-title":"Donor characteristics as pretransplant predictive factors of long-term outcomes after allogeneic peripheral blood stem cell transplantation from HLA-matched related and unrelated donors in patients with hematologic malignancies","volume":"120","author":"Sophie","year":"2012","journal-title":"Blood (ASH annual meeting abstracts)"},{"key":"10.1016\/j.critrevonc.2015.03.004_bib0325","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/bmt.2013.14","article-title":"Donor choice according to age for allo-SCT for AML in complete remission","volume":"48","author":"Ayuk","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.critrevonc.2015.03.004_bib0330","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/bmt.2011.69","article-title":"Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS","volume":"47","author":"Luger","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.critrevonc.2015.03.004_bib0335","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1002\/hon.823","article-title":"Prognostic factors for patients with acute myeloid leukaemia or high-risk myelodysplastic syndromes undergoing myeloablative or non-myeloablative allogeneic blood stem cell transplantation","volume":"25","author":"Graef","year":"2007","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.critrevonc.2015.03.004_bib0340","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1200\/JCO.2012.46.8652","article-title":"Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis","volume":"31","author":"Koreth","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2015.03.004_bib0345","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.bbmt.2012.05.003","article-title":"Allogeneic hematopoietic cell transplantation in patients age 60\u201370 years with de novo high-risk myelodysplastic syndrome or secondary acute myelogenous leukemia: comparison with patients lacking donors who received azacitidine","volume":"18","author":"Platzbecker","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.critrevonc.2015.03.004_bib0350","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1016\/j.bbmt.2014.06.010","volume":"20","author":"Saber","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.critrevonc.2015.03.004_bib0355","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1056\/NEJMoa1203517","article-title":"Peripheral-blood stem cells versus bone marrow from unrelated donors","volume":"367","author":"Anasetti","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.critrevonc.2015.03.004_bib0360","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1200\/JCO.2013.52.3381","article-title":"Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation","volume":"32","author":"Bejar","year":"2014","journal-title":"J Clin Oncol"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842815000517?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842815000517?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,24]],"date-time":"2018-09-24T01:26:09Z","timestamp":1537752369000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842815000517"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["S1040842815000517"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2015.03.004","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2015,8]]}}}